Hikma Pharmaceuticals USA Inc. announced the receipt of FDA approval for its Abbreviated New Drug Application (ANDA040881) for hydrocodone bitartrate and acetaminophen, enhancing its portfolio of generic narcotic pain relievers. This regulatory milestone strengthens Hikma's competitive position in the generic marketplace by expanding its distribution and revenue potential for widely utilized combination products.